125 related articles for article (PubMed ID: 8110925)
1. Effectiveness of an oral triazole for opportunistic mold infections in patients with cancer: experience with SCH 39304.
Anaissie EJ; Kontoyiannis DP; Vartivarian S; Kantarjian HM; O'Brien S; Giralt SA; Andersson BS; Karl C; Champlin RE; Bodey GP
Clin Infect Dis; 1993 Dec; 17(6):1022-31. PubMed ID: 8110925
[TBL] [Abstract][Full Text] [Related]
2. Posaconazole: an extended-spectrum triazole antifungal agent.
Schiller DS; Fung HB
Clin Ther; 2007 Sep; 29(9):1862-86. PubMed ID: 18035188
[TBL] [Abstract][Full Text] [Related]
3. Posaconazole: SCH 56592.
Adis International Ltd
Drugs R D; 2003; 4(4):258-63. PubMed ID: 12848593
[TBL] [Abstract][Full Text] [Related]
4. Safety of triazole antifungal drugs in patients with cancer.
Cronin S; Chandrasekar PH
J Antimicrob Chemother; 2010 Mar; 65(3):410-6. PubMed ID: 20035021
[TBL] [Abstract][Full Text] [Related]
5. Voriconazole versus amphotericin B in cancer patients with neutropenia.
Jørgensen KJ; Gøtzsche PC; Johansen HK
Cochrane Database Syst Rev; 2006 Jan; (1):CD004707. PubMed ID: 16437492
[TBL] [Abstract][Full Text] [Related]
6. Recombinant interferon gamma1b immune enhancement in 20 patients with hematologic malignancies and systemic opportunistic infections treated with donor granulocyte transfusions.
Safdar A; Rodriguez GH; Lichtiger B; Dickey BF; Kontoyiannis DP; Freireich EJ; Shpall EJ; Raad II; Kantarjian HM; Champlin RE
Cancer; 2006 Jun; 106(12):2664-71. PubMed ID: 16691620
[TBL] [Abstract][Full Text] [Related]
7. Safety, plasma concentrations, and efficacy of high-dose fluconazole in invasive mold infections.
Anaissie EJ; Kontoyiannis DP; Huls C; Vartivarian SE; Karl C; Prince RA; Bosso J; Bodey GP
J Infect Dis; 1995 Aug; 172(2):599-602. PubMed ID: 7622915
[TBL] [Abstract][Full Text] [Related]
8. Review: voriconazole for prevention or treatment of invasive fungal infections in cancer with neutropenia.
Morris AM
Ann Intern Med; 2014 Jul; 161(2):JC8. PubMed ID: 25023274
[No Abstract] [Full Text] [Related]
9. The impact of prior invasive mold infections in leukemia patients who undergo allo-SCT in the era of triazole-based secondary prophylaxis.
Georgiadou SP; Lewis RE; Best L; Torres HA; Champlin RE; Kontoyiannis DP
Bone Marrow Transplant; 2013 Jan; 48(1):141-3. PubMed ID: 22635244
[No Abstract] [Full Text] [Related]
10. Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections.
Raad II; Graybill JR; Bustamante AB; Cornely OA; Gaona-Flores V; Afif C; Graham DR; Greenberg RN; Hadley S; Langston A; Negroni R; Perfect JR; Pitisuttithum P; Restrepo A; Schiller G; Pedicone L; Ullmann AJ
Clin Infect Dis; 2006 Jun; 42(12):1726-34. PubMed ID: 16705579
[TBL] [Abstract][Full Text] [Related]
11. Clinical efficacy and safety of primary antifungal prophylaxis with posaconazole versus fluconazole in allogeneic blood hematopoietic stem cell transplantation recipients-A retrospective analysis of a single medical center in Taiwan.
Wang CH; Kan LP; Lin HA; Chang FY; Wang NC; Lin TY; Chao TY; Kao WY; Ho CL; Chen YC; Dai MS; Chang PY; Wu YY; Lin JC
J Microbiol Immunol Infect; 2016 Aug; 49(4):531-8. PubMed ID: 25440977
[TBL] [Abstract][Full Text] [Related]
12. Use of voriconazole to successfully treat disseminated Trichosporon asahii infection in a patient with acute myeloid leukaemia.
Fournier S; Pavageau W; Feuillhade M; Deplus S; Zagdanski AM; Verola O; Dombret H; Molina JM
Eur J Clin Microbiol Infect Dis; 2002 Dec; 21(12):892-6. PubMed ID: 12525928
[TBL] [Abstract][Full Text] [Related]
13. Galactomannan-guided preemptive vs. empirical antifungals in the persistently febrile neutropenic patient: a prospective randomized study.
Tan BH; Low JG; Chlebicka NL; Kurup A; Cheah FK; Lin RT; Goh YT; Wong GC
Int J Infect Dis; 2011 May; 15(5):e350-6. PubMed ID: 21397541
[TBL] [Abstract][Full Text] [Related]
14. [Fluconazole treatment of systemic mycoses].
Mori T; Matsumura M; Ebe T; Takahashi M; Kohara T; Inagaki M; Isonuma H; Hibiya I; Hamamoto T; Watanabe K
Jpn J Antibiot; 1989 Jan; 42(1):55-62. PubMed ID: 2540368
[TBL] [Abstract][Full Text] [Related]
15. Fluconazole versus mould-active triazoles for primary antifungal prophylaxis in adult patients with acute lymphoblastic leukemia: clinical outcome and cost-effectiveness analysis.
Wang Y; Xing Y; Chen L; Meng T; Li Y; Xie J; Chen L; Dong Y; Dong W
Int J Hematol; 2018 Feb; 107(2):235-243. PubMed ID: 29027638
[TBL] [Abstract][Full Text] [Related]
16. Fungal infection from Fusarium spp. in children with refractory hematologic malignancies.
Taçyildiz N; Yavuz G; Unal E; Gözdasoğlu S; Ertem M; Aysev D
Med Pediatr Oncol; 1999 Dec; 33(6):596-7. PubMed ID: 10573590
[No Abstract] [Full Text] [Related]
17. Posaconazole: Use in the Prophylaxis and Treatment of Fungal Infections.
Clark NM; Grim SA; Lynch JP
Semin Respir Crit Care Med; 2015 Oct; 36(5):767-85. PubMed ID: 26398542
[TBL] [Abstract][Full Text] [Related]
18. Voriconazole : a review of its use in the management of invasive fungal infections.
Scott LJ; Simpson D
Drugs; 2007; 67(2):269-98. PubMed ID: 17284090
[TBL] [Abstract][Full Text] [Related]
19. Oral voriconazole for empiric antifungal treatment in patients with uncomplicated febrile neutropenia.
Przepiorka D; Buadi FK; McClune B
Pharmacotherapy; 2008 Jan; 28(1):58-63. PubMed ID: 18154475
[TBL] [Abstract][Full Text] [Related]
20. New approaches to antifungal chemotherapy.
Viviani MA; de Marie S; Graybill JR; Yamaguchi H; Anaissie E; Caillot D
Med Mycol; 1998; 36 Suppl 1():194-206. PubMed ID: 9988508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
